MCM
ABEO icon

Moore Capital Management’s Abeona Therapeutics ABEO Stock Holding History

Moore Capital Management’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-4,000
Closed -$1.58M – 243
2017
Q4 		$1.58M Buy
4,000
+3,000
+300% +$1.24M 0.03% 194
2017
Q3 		$426K Sell
1,000
-3,000
-75% -$806K 0.01% 212
2017
Q2 		$640K Sell
4,000
-2,000
-33% -$273K 0.02% 171
2017
Q1 		$750K Hold
6,000
– – 0.02% 171
2016
Q4 		$728K Buy
+6,000
New +$940K 0.02% 151

Other funds holding ABEO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Moore Capital Management's ABEO Position: Q1 2018 in Review

Moore Capital Management sold out of Abeona Therapeutics (ABEO) in Q1 2018, closing a stake of 4,000 shares — an estimated $1.58M sold.

Moore Capital Management first reported a position in ABEO in Q4 2016 and held it in 5 quarters. The position peaked at $1.58M in Q4 2017. 88 funds tracked by Wall St. Rank hold ABEO as of Q1 2018.

  • Moore Capital Management reported no remaining Abeona Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Moore Capital Management sold 4,000 Abeona Therapeutics shares in Q1 2018, an estimated $1.58M.
  • Moore Capital Management first reported a position in Abeona Therapeutics in Q4 2016 and held it in 5 quarters.
  • Moore Capital Management's Abeona Therapeutics position peaked at $1.58M in Q4 2017.
  • 88 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2018.

Based on Moore Capital Management's 13F filing for Q1 2018, filed 15 May 2018.